Colonial Trust Co SC Has $35,000 Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Colonial Trust Co SC grew its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 84.8% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 85 shares of the company’s stock after purchasing an additional 39 shares during the period. Colonial Trust Co SC’s holdings in IDEXX Laboratories were worth $35,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Hurley Capital LLC bought a new stake in IDEXX Laboratories during the fourth quarter worth about $29,000. Rialto Wealth Management LLC bought a new stake in IDEXX Laboratories during the 4th quarter worth approximately $30,000. Retirement Wealth Solutions LLC bought a new stake in IDEXX Laboratories during the 4th quarter worth approximately $31,000. Kestra Investment Management LLC acquired a new stake in IDEXX Laboratories during the 4th quarter valued at $38,000. Finally, Itau Unibanco Holding S.A. raised its position in IDEXX Laboratories by 540.0% in the 4th quarter. Itau Unibanco Holding S.A. now owns 96 shares of the company’s stock valued at $40,000 after purchasing an additional 81 shares during the last quarter. Institutional investors own 87.84% of the company’s stock.

Insider Buying and Selling at IDEXX Laboratories

In related news, EVP George Fennell sold 9,986 shares of the company’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the sale, the executive vice president now owns 8,176 shares in the company, valued at $3,781,645.28. This represents a 54.98 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 0.98% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on IDXX shares. StockNews.com upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Friday. Barclays boosted their target price on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 4th. Morgan Stanley increased their price target on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the company an “overweight” rating in a research note on Monday, May 5th. Piper Sandler upped their price objective on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a “neutral” rating in a report on Monday, February 10th. Finally, Stifel Nicolaus lowered their target price on IDEXX Laboratories from $450.00 to $420.00 and set a “hold” rating for the company in a research note on Monday, April 14th. Three analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $524.75.

IDEXX Laboratories Stock Up 0.4 %

NASDAQ:IDXX opened at $491.70 on Friday. The stock’s fifty day simple moving average is $423.31 and its 200-day simple moving average is $429.36. The firm has a market capitalization of $39.85 billion, a P/E ratio of 46.08, a P/E/G ratio of 3.41 and a beta of 1.52. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $548.88.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Thursday, May 1st. The company reported $2.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.93 by $0.03. The company had revenue of $998.43 million during the quarter, compared to analyst estimates of $998.25 million. IDEXX Laboratories had a return on equity of 55.82% and a net margin of 22.78%. The company’s revenue for the quarter was up 3.6% compared to the same quarter last year. During the same period in the previous year, the company earned $2.71 EPS. Equities research analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.